Effectiveness of Interventional Therapy for Non-Flow-Limiting Vulnerable Plaques

NCT06855537

Status	RECRUITING
Phase	Phase 4
Sponsor	Beijing Anzhen Hospital
Enrollment	2,190 participants

Key Eligibility Criteria

Inclusion (5)

- Successful completion of angiography, QFR, and OCT examinations
- Successful treatment of all culprit lesions and flow-limited lesions (QFR d 0.8)
- Reference vessel diameter between 2.5-4.0 mm on imaging assessment
- Lesion length d40 mm
- At least one significant stenosis (diameter reduction \>50%) demonstrated by angiography, with QFR \>0.80 and OCT-defined TCFA (fibrous cap thickness \<65㎛, lipid arc \>90°)

Exclusion (8)

- Patients with contraindications to dual antiplatelet therapy (DAPT) or planning to discontinue DAPT within one year
- Patients with other major illnesses and a life expectancy \<2 years
- Patients scheduled for cardiac surgery or major non-cardiac surgery
- Women who are breastfeeding, pregnant, or planning pregnancy during the study
- Patients with severe heart failure (NYHA class III-IV or Killip class III-IV or left ventricular ejection fraction \<35%)

... and 3 more (see full listing online)

Locations (1 total)

Beijing Anzhen Hospital, Beijing, Beijing Municipality, China